Marilyn Huckans1,2,3,4, Clare J Wilhelm1,2, Tamara J Phillips1,4,5, Elaine T Huang1,4, Rebekah Hudson1, Jennifer M Loftis1,2,4. 1. Research and Development Service, VA Portland Health Care System, Portland, Oregon, USA. 2. Department of Psychiatry, Oregon Health and Science University, Portland, Oregon, USA. 3. Mental Health and Clinical Neurosciences Division, VA Portland Health Care System, Portland, Oregon, USA. 4. Methamphetamine Abuse Research Center, Oregon Health and Science University, Portland, Oregon, USA. 5. Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon, USA.
Abstract
BACKGROUND: Methamphetamine (MA) abuse causes immune dysfunction and neuropsychiatric impairment. The mechanisms underlying these deficits remain unidentified. METHODS: The effects of MA on anxiety-like behavior and immune function were investigated in mice selectively bred to voluntarily consume high amounts of MA [i.e., MA high drinking (MAHDR) mice]. MA (or saline) was administered to mice using a chronic (14-day), binge-like model. Performance in the elevated zero maze (EZM) was determined 5 days after the last MA dose to examine anxiety-like behavior. Cytokine and chemokine expressions were measured in the hippocampus using quantitative polymerase chain reaction (qPCR). Human studies were also conducted to evaluate symptoms of anxiety using the General Anxiety Disorder-7 Scale in adults with and without a history of MA dependence. Plasma samples collected from human research participants were used for confirmatory analysis of murine qPCR results using an enzyme-linked immunosorbent assay. RESULTS: During early remission from MA, MAHDR mice exhibited increased anxiety-like behavior on the EZM and reduced expression of chemokine (C-C motif) ligand 3 (ccl3) in the hippocampus relative to saline-treated mice. Human adults actively dependent on MA and those in early remission had elevated symptoms of anxiety as well as reductions in plasma levels of CCL3, relative to adults with no history of MA abuse. CONCLUSIONS: The results highlight the complex effects of MA on immune and behavioral function and suggest that alterations in CCL3 signaling may contribute to the mood impairments observed during remission from MA addiction.
BACKGROUND:Methamphetamine (MA) abuse causes immune dysfunction and neuropsychiatric impairment. The mechanisms underlying these deficits remain unidentified. METHODS: The effects of MA on anxiety-like behavior and immune function were investigated in mice selectively bred to voluntarily consume high amounts of MA [i.e., MA high drinking (MAHDR) mice]. MA (or saline) was administered to mice using a chronic (14-day), binge-like model. Performance in the elevated zero maze (EZM) was determined 5 days after the last MA dose to examine anxiety-like behavior. Cytokine and chemokine expressions were measured in the hippocampus using quantitative polymerase chain reaction (qPCR). Human studies were also conducted to evaluate symptoms of anxiety using the General Anxiety Disorder-7 Scale in adults with and without a history of MA dependence. Plasma samples collected from human research participants were used for confirmatory analysis of murine qPCR results using an enzyme-linked immunosorbent assay. RESULTS: During early remission from MA, MAHDR mice exhibited increased anxiety-like behavior on the EZM and reduced expression of chemokine (C-C motif) ligand 3 (ccl3) in the hippocampus relative to saline-treated mice. Human adults actively dependent on MA and those in early remission had elevated symptoms of anxiety as well as reductions in plasma levels of CCL3, relative to adults with no history of MA abuse. CONCLUSIONS: The results highlight the complex effects of MA on immune and behavioral function and suggest that alterations in CCL3 signaling may contribute to the mood impairments observed during remission from MA addiction.
Authors: J M Wheeler; C Reed; S Burkhart-Kasch; N Li; C L Cunningham; A Janowsky; F H Franken; K M Wiren; J G Hashimoto; A C Scibelli; T J Phillips Journal: Genes Brain Behav Date: 2009-07-21 Impact factor: 3.449
Authors: Rebecca McKetin; Sharon Dawe; Richard A Burns; Leanne Hides; David J Kavanagh; Maree Teesson; Ross McD Young; Alexandra Voce; John B Saunders Journal: Drug Alcohol Depend Date: 2016-01-30 Impact factor: 4.492
Authors: Andrew J Levine; Sandra Reynolds; Christopher Cox; Eric N Miller; Janet S Sinsheimer; James T Becker; Eileen Martin; Ned Sacktor Journal: J Neurovirol Date: 2014-04-16 Impact factor: 2.643
Authors: N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong Journal: Eur Neuropsychopharmacol Date: 2007-08-03 Impact factor: 4.600
Authors: Shkelzen Shabani; Sydney K Houlton; Laura Hellmuth; Erika Mojica; John R K Mootz; Zhen Zhu; Cheryl Reed; Tamara J Phillips Journal: Front Neurosci Date: 2016-11-02 Impact factor: 4.677
Authors: Mircea Radu Mihu; Jessica Roman-Sosa; Avanish K Varshney; Eliseo A Eugenin; Bhavikkumar P Shah; Hiu Ham Lee; Long N Nguyen; Allan J Guimaraes; Bettina C Fries; Joshua D Nosanchuk; Luis R Martinez Journal: mBio Date: 2015-10-27 Impact factor: 7.867
Authors: Gabriella Shab; Elissa K Fultz; Ariana Page; Michal A Coelho; Lindsey W Brewin; Nicholas Stailey; Chelsea N Brown; Camron D Bryant; Tod E Kippin; Karen K Szumlinski Journal: Behav Brain Res Date: 2020-10-11 Impact factor: 3.332
Authors: Jennifer M Loftis; Michael Lasarev; Xiao Shi; Jodi Lapidus; Aaron Janowsky; William F Hoffman; Marilyn Huckans Journal: PLoS One Date: 2019-10-10 Impact factor: 3.240